Quantori

Quantori

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Quantori is a specialized technology services and platform provider for the biopharma and healthcare industries, operating at the intersection of advanced AI and deep scientific domain knowledge. The company has evolved from a pure IT services model to develop its own proprietary AI platform, Q-Suite, which includes predictive ADMET models and agentic AI tools designed to accelerate R&D. With a client base that includes 12 of the top 15 pharmaceutical companies and over 30 innovative startups, Quantori leverages a globally distributed team of engineers, data scientists, and MDs/PhDs to deliver scalable, AI-enabled solutions that address complex challenges from discovery to delivery.

AI / Machine LearningDrug Delivery

Technology Platform

Q-Suite™, a modular agentic AI platform for life sciences featuring Q-Models (predictive ADMET ML models), Q-Scientist (digital lab automation), and Q-Portal (governance for LLMs).

Funding History

2
Total raised:$10M
Series A$8M
Seed$2M

Opportunities

The massive and growing demand for AI and digital transformation in biopharma R&D presents a significant opportunity.
Quantori's dual model of deep-domain services and a proprietary AI platform (Q-Suite) allows it to capture value from both implementation projects and scalable software licenses, particularly with high-need tools like predictive ADMET models.

Risk Factors

The company faces intense competition for both talent and clients from large IT consultancies and specialized AI software firms.
Its service-heavy model may limit scalability, and its success is tied to the cyclical R&D spending of biopharma clients.
Rapid technological change in AI requires continuous and costly platform innovation to maintain a competitive edge.

Competitive Landscape

Quantori competes in a crowded field including global IT and consulting giants (e.g., Accenture, IQVIA), specialized bioinformatics software companies (e.g., DNAnexus, Benchling), and pure-play AI/ML drug discovery platforms (e.g., Schrödinger, Recursion, Exscientia). Its differentiation lies in its deep scientific domain expertise combined with full-stack engineering services and its emerging focus on agentic AI platforms tailored for life sciences.